Compare MAIN & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | STVN |
|---|---|---|
| Founded | 2007 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Containers/Packaging |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 2014 | 2021 |
| Metric | MAIN | STVN |
|---|---|---|
| Price | $58.28 | $22.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $61.57 | $25.67 |
| AVG Volume (30 Days) | ★ 580.1K | 443.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.04% | 0.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.27 | $9.67 |
| Revenue Next Year | $5.14 | $9.99 |
| P/E Ratio | $62.55 | ★ $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.95 | $12.89 |
| 52 Week High | $67.26 | $28.00 |
| Indicator | MAIN | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.02 | 67.99 |
| Support Level | $54.60 | $20.34 |
| Resistance Level | $59.55 | $24.01 |
| Average True Range (ATR) | 1.17 | 0.73 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 74.99 | 98.68 |
Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.